Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanifibranor - Inventiva Pharma

Next Previous
Drug Profile

Lanifibranor - Inventiva Pharma

Alternative Names: IVA-337

Latest Information Update: 04 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inventiva Pharma
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antineoplastics; Benzothiazoles; Butyric acids; Halogenated hydrocarbons; Hepatoprotectants; Indoles; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Fibrosis; Non-alcoholic steatohepatitis
  • Phase II Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • No development reported Bladder cancer; Liver cirrhosis
  • Discontinued Systemic scleroderma

Most Recent Events

  • 04 Jun 2025 Lanifibranor - Inventiva Pharma is available for licensing as of 23 May 2025. http://www.inventivapharma.com
  • 01 Apr 2025 Inventiva completes enrolment in its phase-III NATiV3 clinical trials in Non-alcoholic steatohepatitis in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Mexico, Multinational, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Scotland, South Africa, Spain, Sweden, Ukraine, United Kingdom, USA (PO) (NCT04849728) (EudraCT2020-004986-38)
  • 05 Mar 2025 Inventiva Pharma plans a phase III pivotal trial for Non-alcoholic steatohepatitis in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top